Sellas Life Sciences: 'Hold' As Phase 3 AML Study Progresses To Key Event

SELLAS Life Sciences (SLS) is rated 'Hold' due to pending phase 3 REGAL data for GPS in AML after CR2, a major 2026 catalyst.

Caris Life Sciences Publishes Study Validating Caris AI Insights for Temozolomide Benefit in Glioblastoma Patients

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...
Seeking Alpha

Sellas Life Sciences: Tons Of Completed Studies

SELLAS Life Sciences' value hinges on the pivotal REGAL phase 3 trial in AML, with interim results showing promise, but final outcomes still unknown. Despite encouraging data, I remain highly cautious ...

LIR Life Sciences Launches Ex Vivo Animal Study to Evaluate Protamine Enhanced Transdermal Transport of Larger Format Therapeutic Molecules

VANCOUVER, BC / ACCESS Newswire / April 28, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company) is pleased to announce, further to its news ...
Business Wire

Builds Bio+ Releases New York / London Life Sciences Study Tour Research Report

NEW YORK--(BUSINESS WIRE)--Builds Bio+, the premier life science membership organization that connects all segments of the life sciences ecosystem across major regional clusters, today announced the ...
CNBC

Anthropic launches Claude Life Sciences to give researchers an AI efficiency boost

Anthropic announced Claude for Life Sciences, an AI integration for researchers to advance scientific discovery. Claude for Life Sciences is built around Anthropic's existing AI models and supports ...

Lir Life Sciences Corp.: LIR Life Sciences Launches Ex Vivo Animal Study to Evaluate Protamine Enhanced Transdermal Transport of Larger Format Therapeutic Molecules

VANCOUVER, BC / ACCESS Newswire / April 28, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company) is pleased to announce, further to its news re ...